Quinpramine is a novel compound effective in ameliorating brain autoimmune disease

Mahendra P. Singh, Gerd Meyer zu Hörste, Wei Hu, Anne K. Mausberg, Petra D. Cravens, Todd Eagar, Stefan Löber, Ralf Klingenstein, Peter Gmeiner, Carsten Korth, Bernd C. Kieseier, Olaf Stüve

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Acridine-iminodibenzyl chimeric compounds were previously introduced as a class of cholesterol-redistributing substances with antiprion effects. Here, we show that administration of the lead compound quinpramine to mice with experimental autoimmune encephalitis, an animal model of multiple sclerosis (MS), significantly ameliorates disease in preventive and therapeutic paradigms. Quinpramine treatment decreased the number of inflammatory CNS lesions, antigen-specific T-cell proliferation, and pro-inflammatory cytokines IFNγ and IL-17. Quinpramine is thus an immunoregulatory drug that is a candidate pharmaceutical for MS.

Original languageEnglish (US)
Pages (from-to)397-400
Number of pages4
JournalExperimental Neurology
Issue number2
StatePublished - Feb 2009

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience


Dive into the research topics of 'Quinpramine is a novel compound effective in ameliorating brain autoimmune disease'. Together they form a unique fingerprint.

Cite this